“Over the past 13 years, I had the greatest opportunity to exploit my passion for science at IPST by contributing to the design, and validation of unique assays which are now routinely run and serve to quantify the efficacy in preclinical drug candidates. My greatest contribution was to see the increase in demand for efficacy services such as the rodent model of pulmonary arterial hypertension (PAH), as well as our intravascular thrombosis and hemostasis models.” Charles completed his doctorate in Pharmacology at the Université de Montreal followed by 4 years of post doctorate studies at the University of Pittsburgh in the Department of Molecular Genetics and Biochemistry. His field of expertise includes cardiovascular pharmacology and molecular biology.
Connect with Charles-E. Laurent
Acute pulmonary hypertension
Purpose
To assess the effect of antihypertensive agents on pulmonary artery pressure.
Method
Anesthetized rats are ventilated with hypoxic air (or IV injected with U46619) while saturation and pulmonary pressure is monitored. Once stable elevated PAP is achieved antihypertensive drugs are tested for efficacy.
Study Outcome
- Hemodynamic parameters; mPAP, mSAP, Pulse Pressure, PVR, Heart rate, saturation
Compliance
Non-GLP
Species
Rats
Charles-E. Laurent
Ph.D., Director of In-Vivo Pharmacology
